Pelvic exenteration, University of Michigan: 100 patients at 5 years

Morley, George W.; Hopkins, M.P.; Lindenauer, S. Martin; Roberts, J. A.

doi:10.1016/0020-7292(90)90382-u

Cited by 78 publications

(115 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…With respect to surgical treatment for residual disease after radiation therapy, the most effective method is probably pelvic exenteration (Stanhope et al, 1990). Total pelvic exenteration offers a 5-year survival rate of 23 -50%, but it requires alterations of both the urinary and lower gastrointestinal tracts, and a high rate of Hysterectomy for residual disease in cervical cancer T Ota et al severe postoperative complications, such as infection, injury of the urinary and lower gastrointestinal tracts, and small-bowel obstruction, occur, in addition to a 4 -14% surgery-related mortality rate (Rutledge et al, 1977;Morley et al, 1989;Shingleton et al, 1989;Matthews et al, 1992;Moutardier et al, 2004). The utility of radical hysterectomy, a more conservative procedure, has been reported, but it also has a high rate of complications.…”

Section: Discussionmentioning

confidence: 99%

Adjuvant hysterectomy for treatment of residual disease in patients with cervical cancer treated with radiation therapy

et al. 2008

View full text Add to dashboard Cite

The objective of this retrospective study was to determine the efficacy of adjuvant hysterectomy for treatment of residual disease in cervical carcinoma treated with radiation therapy. Between 1971 and 1996, 1590 patients with carcinoma of the uterine cervix (stages I -IIIb) were treated with radiation therapy. Three months after completion of radiation therapy, the status of local control was investigated, and total abdominal hysterectomy was performed in cases in which central residual disease existed in the cervix. Of the 1590 patients, residual disease was identified in 162 patients. Among these patients, 35 showed an absence of distant metastasis or lateral parametrial invasion and underwent hysterectomy. The overall 5-and 10-year survival rates for these patients were 68.6 and 65.7%, respectively. There was no significant difference in survival between patients with squamous cell carcinoma and those with non-squamous cell carcinoma or between patients with stage I/II carcinoma and those with stage III carcinoma. With respect to treatment-related morbidity, five (14.3%) patients suffered grade III or IV complications after hysterectomy. Adjuvant hysterectomy is an effective addition to radiation therapy in the treatment of cervical cancer, even in patients with stage III disease and in those with non-squamous cell carcinoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Adjuvant hysterectomy for treatment of residual disease in patients with cervical cancer treated with radiation therapy

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Selected patients with such a recurrence may be candidates for pelvic exenteration [21,22]. Pelvic exenteration has been associated with significant operative morbidity and poor overall survival in the setting of recurrent endometrial cancer [21,22].…”

Section: Surgery For Stage IV and Recurrent Endometrial Cancermentioning

confidence: 99%

Treatment for Advanced and Recurrent Endometrial Carcinoma: Combined Modalities

Rauh‐Hain

Carmen

2010

The Oncologist

View full text Add to dashboard Cite

After completing this course, the reader will be able to:1. Discuss the role of radiation therapy for advanced stage endometrial cancer in order to differentiate between patients who should receive only radiation therapy and patients requiring surgery and/or chemotherapy in addition to radiation.2. Evaluate the role of surgery for stage IV and recurrent endometrial cancer in order to select patients most likely to benefit from cytoreductive surgery.3. Evaluate the role of chemotherapy, particularly in conjunction with radiotherapy, in advanced stage endometrial carcinoma and select appropriate candidates for multimodality therapy.This article is available for continuing medical education credit at CME.TheOncologist.com. CME CME ABSTRACTWomen with recurrent or advanced endometrial cancer constitute a heterogeneous group of patients. Depending on previous treatment, women with recurrent endometrial cancer may be appropriate candidates for surgery, radiation therapy, hormonal therapy, or chemotherapy. Women with advanced stage disease at presentation may also be appropriate candidates for systemic and local therapies. We review the treatment options available to treat recurrent and locally advanced endometrial cancer. Treatment choice depends largely on the localization of disease, the patient's performance status and previ-

show abstract

“…Aleksic beschreibt in seiner Arbeit ein Durchschnittsalter von 59,8 Jahren (Aleksic et al, 1998). Eine ähnliche Altersverteilung eruierten in ihren Auswertungen Kolbert (60 Jahre (28 -87 Jahre)), Hafner (60 Jahre (19 -83)), Pinelo (55,7 Jahre), Fleisch (55 Jahre (22 -77 Jahre)), Morley (53 Jahre (21 -74 Jahre)) und Crozier (47 Jahre (22 -70 Jahre)) (Crozier et al, 1995;Kolbert et al, 1997;Morley et al, 1989;Hafner et al, 1992;Pinelo et al, 2006;Fleisch et al, 2007). In der Studie von Berek reichte das Altersspektrum von 26 bis 74 Jahren (Berek et al, 2005).…”

Section: Altersverteilungunclassified

“…Der Anteil der Zervixkarzinome liegt bei 13 -97%, der der Vulvakarzinome bei 1 -61%, der der Korpuskarzinome bei 2-13%, der der Vaginalkarzinome bei 2 -14%, der der Ovarialkarzinome und der der Sarkome bei 1 -8% (Brunschwig, 1959;Kiselow, 1967;Rodriguez-Bigas et al, 1996;Aleksic et al, 1998;Houvenaeghel et al, 2004;Durgatosh et al, 2004;Berek et al, 2005;Lambrou et al, 2005;Morley et al, 1989;Goldberg et al, 2006;Wydra et al, 2006;Pinelo et al, 2006;Mourton et al, 2006;Fleisch et al, 2007). Die meisten Autoren sehen allerdings ein lokal fortgeschrittenes oder ein rezidivierendes Zervixkarzinom, welches sich durch ein vorzugsweise lokales Wachstum und erst spätere Fernmetastasierung ausgezeichnet, als die häufigste Indikation zur Exenteration (Brunschwig, 1960;Kiselow, 1967;Di Saia et al, 1973;Rodriguez-Bigas et al, 1996;Petri, 2001;Hillemans et al, 2004;Lambrou et al, 2005).…”

Section: Indikationunclassified

“…Die meisten Autoren beschreiben den negativen Nodalstatus, eine R0-Resektion und einen kurativen Therapieansatz als wichtigste prognostische Faktoren für die Gesamtüberlebenszeit (Morley et al, 1989;Vermaas et al, 2007;Teran-Porcayo et al, 2006;Nguyen et al, 2005;Lopez et al, 2004;Aleksic et al, 1998;Durgatosh et al, 2004;Koehler et al, 2006;Fleisch et al, 2007 (Hatch et al, 1988;Morley et al, 1989;Sharma et al, 2005 (Hatch et al, 1988;de Wilt et al, 2006;Koehler et al, 2006;Morley et al, 1989 …”

Section: Gesamtüberlebensratenunclassified

See 1 more Smart Citation

Behandlungsergebnisse der exenterativen Eingriffe bei gynäkologischen Malignomen an der Frauenklinik im Klinikum Kassel

Bogdanova¹

2008

Geburtsh Frauenheilk

View full text Add to dashboard Cite

Pelvic exenteration, University of Michigan: 100 patients at 5 years

Cited by 78 publications

References 0 publications

Adjuvant hysterectomy for treatment of residual disease in patients with cervical cancer treated with radiation therapy

Adjuvant hysterectomy for treatment of residual disease in patients with cervical cancer treated with radiation therapy

Treatment for Advanced and Recurrent Endometrial Carcinoma: Combined Modalities

Behandlungsergebnisse der exenterativen Eingriffe bei gynäkologischen Malignomen an der Frauenklinik im Klinikum Kassel

Contact Info

Product

Resources

About